The Latest Cardiac and Vascular News
Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. This may include, but is not limited to, discussions with investment bankers, equity fund […]
More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and […]
LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced that an investigator initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients […]
Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced the Company’s registration statement on Form S-1 relating to its equity credit line with Calvary Fund I LP has been ordered effective by the Securities and Exchange Commission. This equity […]
Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announces financial and operating results for the first quarter ended March 31, 2020. Company improved financial and operating results are reflected in every major financial category, as compared to first quarter […]
Agreement Provides Flexible Access to Funding at a Lower Cost of Capital Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) announced today it has executed a new Equity Line Purchase Agreement with Cavalry Fund I, LP (“Cavalry”) to sell up […]
Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today reported financial results for fiscal year ended December 31, 2019. Key Financial Highlights: Revenues for the year ended December 31, 2019 increased by 273% to $310,164, as compared to $83,263 in […]
Los Angeles, CA, March 02, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announced it has filed an 8K with the Securities and Exchange Commission (SEC) regarding a presentation on SofPulse® their companies flagship Electroceutical® device. The 8K will be utilized to expand the current US […]
Los Angeles, CA, Feb. 04, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) is pleased to announce the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. Through the amended terms in the […]
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDVD / ENDV) (“Endonovo” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 15217855, which […]
